355 related articles for article (PubMed ID: 7914767)
21. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
Kolár Z; Murray PG; Zapletalová J
Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
23. HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon AK; Clark GM; Chamness GC; Ullrich A; McGuire WL
J Clin Oncol; 1989 Aug; 7(8):1120-8. PubMed ID: 2569032
[TBL] [Abstract][Full Text] [Related]
24. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583
[TBL] [Abstract][Full Text] [Related]
25. Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast.
Cho LC; Hsu YH
Kaohsiung J Med Sci; 2008 May; 24(5):227-32. PubMed ID: 18508419
[TBL] [Abstract][Full Text] [Related]
26. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.
Keshgegian AA
Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626
[TBL] [Abstract][Full Text] [Related]
27. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
[TBL] [Abstract][Full Text] [Related]
29. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
30. [Expression of oestrogen receptor-beta in invasive breast tumours].
Péter I; Számel I; Péley G
Magy Onkol; 2004; 48(1):63-9. PubMed ID: 15105898
[TBL] [Abstract][Full Text] [Related]
31. Does single receptor positive breast carcinoma differ with regard to age, tumor grade, and HER2 amplification status?
Ozguzer A; Bayol U; Pala EE; Akdeniz CY; Degirmenci M
J BUON; 2016; 21(1):21-6. PubMed ID: 27061526
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
33. Expression of p53, DCC, and HER-2/neu in mucinous carcinoma of the breast.
Hsu YH; Shaw CK
Kaohsiung J Med Sci; 2005 May; 21(5):197-202. PubMed ID: 15960065
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
36. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
37. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis.
Kommoss F; Pfisterer J; Idris T; Giese E; Sauerbrei W; Schäfer W; Thome M; Pfleiderer A
Anal Quant Cytol Histol; 1994 Jun; 16(3):203-10. PubMed ID: 7916848
[TBL] [Abstract][Full Text] [Related]
38. Hormone receptor expression in invasive breast cancer among Korean women and comparison of 3 antiestrogen receptor antibodies: a multi-institutional retrospective study using tissue microarrays.
Bae YK; Gong G; Kang J; Lee A; Cho EY; Lee JS; Suh KS; Lee DW
Am J Surg Pathol; 2012 Dec; 36(12):1817-25. PubMed ID: 23154769
[TBL] [Abstract][Full Text] [Related]
39. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of Her2/neu, estrogen and progesterone receptors in invasive micropapillary carcinoma of the breast.
Kuroda H; Sakamoto G; Ohnisi K; Itoyama S
Breast Cancer; 2004; 11(3):301-6. PubMed ID: 15550850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
